[go: up one dir, main page]

Butters et al., 2005 - Google Patents

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses

Butters et al., 2005

View HTML
Document ID
11335124211277414397
Author
Butters T
Dwek R
Platt F
Publication year
Publication venue
Glycobiology

External Links

Snippet

The inherited metabolic disorders of glycosphingolipid (GSL) metabolism are a relatively rare group of diseases that have diverse and often neurodegenerative phenotypes. Typically, a deficiency in catabolic enzyme activity leads to lysosomal storage of GSL …
Continue reading at academic.oup.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases

Similar Documents

Publication Publication Date Title
Butters et al. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses
Butters et al. Therapeutic applications of imino sugars in lysosomal storage disorders
Platt et al. Substrate reduction therapy
Platt et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy
Mohamed et al. Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises
Fan et al. Active‐site‐specific chaperone therapy for Fabry disease: Yin and Yang of enzyme inhibitors
Wennekes et al. Glycosphingolipids—nature, function, and pharmacological modulation
Dwek et al. Targeting glycosylation as a therapeutic approach
Butters Gaucher disease
Khanna et al. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β‐glucosidase
Chang et al. Hydrophilic iminosugar active‐site‐specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients
Okumiya et al. Chemical chaperones improve transport and enhance stability of mutant α-glucosidases in glycogen storage disease type II
Aerts et al. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention
Sawkar et al. Therapeutic strategies to ameliorate lysosomal storage disorders–a focus on Gaucher disease
Yam et al. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants
Ghisaidoobe et al. Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors
US7528153B2 (en) Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
Yu et al. Isofagomine-and 2, 5-anhydro-2, 5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention
EP0912179B1 (en) Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
US5399567A (en) Method of treating cholera
Jeyakumar et al. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis
Lachmann et al. Substrate reduction therapy for glycosphingolipid storage disorders
Platt et al. Substrate reduction therapy in mouse models of the glycosphingolipidoses
Butters et al. Small–molecule therapeutics for the treatment of glycolipid lysosomal storage disorders
CN102245180A (en) Compositions and methods for the treatment of altered alpha-synuclein function